Amphastar Pharma

Forecast & Rating7 analysts currently cover Amphastar Pharma, with about 0.0% giving a positive rating — meaning they expect the stock to rise. The average price target is $22.50, about 11.9% downside from the current price of $25.54. Price targets span a fair range, indicating some disagreement among institutions. Historically, about 60.9% of past price targets were eventually met, which adds credibility. For you, this means most institutions are cautious on Amphastar Pharma's outlook. Data as of Sep 2, 2026; for reference only and not investment advice.